Development
Sarepta Therapeutics, Inc.
SRPT
$16.75
-$0.35-2.05%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 1.24B | 1.10B | 1.00B | 975.68M | 933.01M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.24B | 1.10B | 1.00B | 975.68M | 933.01M |
| Cost of Revenue | 1.03B | 1.03B | 1.06B | 1.07B | 1.02B |
| Gross Profit | 215.61M | 72.34M | -54.54M | -96.40M | -84.07M |
| SG&A Expenses | 481.87M | 470.65M | 454.54M | 490.30M | 451.42M |
| Depreciation & Amortization | 1.56M | 975.00K | 714.00K | 714.00K | 714.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.51B | 1.50B | 1.51B | 1.56B | 1.47B |
| Operating Income | -267.82M | -399.28M | -509.80M | -587.41M | -536.20M |
| Income Before Tax | -520.10M | -661.78M | -885.02M | -1.10B | -689.96M |
| Income Tax Expenses | 15.88M | 29.10M | 22.66M | 16.69M | 13.53M |
| Earnings from Continuing Operations | -535.98 | -690.88 | -907.68 | -1.12K | -703.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -535.98M | -690.88M | -907.68M | -1.12B | -703.49M |
| EBIT | -267.82M | -399.28M | -509.80M | -587.41M | -536.20M |
| EBITDA | -223.43M | -355.70M | -466.44M | -544.96M | -494.34M |
| EPS Basic | -6.10 | -7.83 | -10.31 | -12.69 | -8.03 |
| Normalized Basic EPS | -1.80 | -2.69 | -3.58 | -4.31 | -4.09 |
| EPS Diluted | -6.16 | -7.83 | -10.32 | -12.70 | -8.04 |
| Normalized Diluted EPS | -1.82 | -2.69 | -3.58 | -4.31 | -4.09 |
| Average Basic Shares Outstanding | 359.44M | 353.66M | 352.40M | 351.16M | 350.23M |
| Average Diluted Shares Outstanding | 371.41M | 353.66M | 352.40M | 351.16M | 350.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |